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Introduction: Of the 10–15% of the population labelled as penicillin allergic, 
≤10% are truly allergic. We examined the safety, effi cacy and post-testing 
utility of strategies to de-label clinically diagnosed penicillin allergy. 
 
Methods: Records of skin testing (ST) and oral challenges (OC) performed 
between June 2008–June 2012 were reviewed. Intradermal ST was performed 
with PPL/MDM (DAP, Diater, Spain), benzylpenicillin, fl ucloxacillin, 
amoxycillin, cephazolin and ceftriaxone. OC with penicillin VK was done 
if ST negative or selectively positive with follow-up OC to other beta-lactams. 
Telephone follow-up aimed to determine patient perception of post-testing 
recommendations and antibiotic exposure. 
 
Results: 48/294 (16.3%) patients tested had a positive ST to ≥1 ST determinant. 
16/48 (33.3%) had a positive reaction to either benzylpenicillin or 
PPL/MDM but not both. 17/48 (35%) patients were ST positive to a single 
beta-lactam determinant with negative tests to benzylpenicillin, PPL and MDM. 2/237 (0.8%) patients who underwent penicillin VK challenge had 
mild positive reactions despite negative ST (NPV 99.1%). To-date 247/294 
(84%) of penicillin allergy labelled patients have been recommended to tolerate 
≥1 beta-lactam antibiotic with some OCs still pending. 143/294 (48.6%) 
of patients were contacted a median of 21 months following testing of which 
49/143 (34.3%) had tolerated a complete course of a beta-lactam antibiotic. 
Overall 16/16 (100%) of ST positive versus 61/117 (52%) of ST negative 
patients contacted were following specifi c post-testing recommendations 
(p < 0.001), and this discrepancy was largely driven by reservation by the 
patient and/or their GP. 
 
Conclusions: ST/OC is a safe and effi cacious way of de-labelling patients 
with a clinical history of penicillin allergy. Use of multiple ST determinants 
maintains a high NPV and identifi es those with a selective beta lactam allergy 
who may benefi t from further OC to clarify their tolerance of other betalactams. 
Imperfect adherence to post-testing recommendations suggests a 
need for better reporting and follow-up communication with the patient and 
their primary physician. 